Dynavax reports updated data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) reported updated response data from the Phase Ib/II MEL-01 (KEYNOTE-184) trial evaluating its SD-101 plus PD-1 inhibitor Keytruda pembrolizumab to treat unresectable stage IIIc or IV melanoma. The data were released in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.

SD-101 is an immunostimulatory sequence (ISS)-based second-generation type C toll-like receptor 9 (TLR9) agonist...